Related to IP-K Extends Collaborations with Sanofi-Aventis R&D and Novartis Tropical Disease Institute

• Sanofi-Aventis to Develop Metabolex’ Type 2 Diabetes Therapy as Part of $375M Deal
  
• Sanofi-Aventis Acquires TargeGen and Inks Partnership with JDRF
  
• Interim Analysis of Novartis’ Osteoarthritis Therapy Suggests Lack of Efficacy Benefit
  
• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Sanofi-Aventis to Fund Personalized Medicine Grants for Scripps Researchers
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• Novartis and Collaborators Discover Candidate for Drug-Resistant Malaria
  
• Warner Chilcott Acquires Sole U.S. Rights to Novartis’ Marketed Overactive Bladder Drug for $400M
  
• Alnylam to Nix Jobs in the Wake of Novartis Collaboration Ending
  
• Sanofi-Aventis Taps Pieris for Anticalin Drug Development for €3.5M
  
• Sanofi-Aventis Sells Two CMC Sites to Covance for $25M in $1–2B Services Deal
  
• Novartis and HGS Ditch HCV Drug as EMEA and FDA Express Risk-Benefit Concerns
  
• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• Novartis Inks U.S. Commercialization Deal for Cepheid’s Ph+ CML Prognostic Tool
  
• Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera
  
• Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs
  
• Asuragen and Novartis to Facilitate Standardization of BCR-ABL1 RT-qPCR Results
  
• Merck KGaA and Sanofi-Aventis to Evaluate Combinations of Phase I Anticancer Compounds
  
• Avila Earns $40M Up Front from sanofi-aventis in Protein Silencing Cancer Partnership
  
• AMT Secures Option to License Sanfilippo B Gene Therapy from Institut Pasteur-Led Consortium